Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

124/433 Matches for
“Epidemiology”

“Epidemiology” Clear all
  1. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

    Schmid P et al. · PLoS One · 2015 Match 100

    ### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…

    FibroTest HCV HIV

  2. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021 Match 100

    ### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…

    ActiTest FibroTest HCV

  3. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 100

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  4. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 99

    ### Background And Aims Despite the high prevalence of chronic hepatitis B (CHB…

    FibroTest HBV

  5. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 99

    ### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…

    FibroTest HCV

  6. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.

    Liu S et al. · PLoS One · 2011 Match 98

    ### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…

    FibroTest HCV

  7. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 98

    FibroTest HCV

  8. Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

    White DL et al. · Dig Dis Sci · 2012 Match 98

    ### Aim We evaluated the association between two medications that alter bioavailable androgen…

    ActiTest FibroTest HCV

  9. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 97

    ### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…

    NashTest SteatoTest Metabolic

  10. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 97

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  11. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 96

    ### Background & Objectives One of the multiple factors contributing to virological response in…

    ActiTest FibroTest SteatoTest HCV

  12. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 96

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  13. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?

    Gentile I et al. · Infez Med · 2014 Match 96

    It is estimated that hepatitis C virus (HCV) infects chronically about 160…

    FibroTest HCV

  14. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.

    Myers RP et al. · Am J Gastroenterol · 2002 Match 95

    ### Objectives Liver fibrosis in chronic hepatitis C is related to sex, age…

    FibroTest HCV

  15. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 95

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  16. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 94

    FibroTest Metabolic

  17. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 94

    Acute hepatitis C virus infection remains a major health concern in human…

    FibroTest HCV HIV

  18. Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.

    Traoré F et al. · BMC Infect Dis · 2015 Match 94

    ### Background Hepatitis B (HB) infection is common in Mali. However, there is…

    ActiTest FibroTest HBV

  19. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 93

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  20. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 93

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  21. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 92

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  22. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 92

    Although most hepatitis C virus (HCV) infections are acquired by injection drug…

    FibroTest

  23. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 92

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  24. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

    Poynard T et al. · Lancet · 1997 Match 91

    ### Background Our aim was to assess the natural history of liver fibrosis…

    HCV

  25. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

    Degos F et al. · J Hepatol · 2010 Match 91

    ### Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that…

    FibroTest HBV HCV HIV

  26. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 90

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  27. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 90

    ### Background Excessive alcohol consumption may lead to the development of alcohol-related…

    FibroTest Alcohol

  28. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 90

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  29. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 89

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  30. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 89

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  31. [Hepatitis B virus genotypes and evolutionary markers in chronic HBsAG patients in Bujumbura].

    Ntagirabiri R et al. · Pan Afr Med J · 2016 Match 88

    ### Introduction Hepatitis B virus infection (VHB) is a serious condition which can…

    FibroTest HBV

  32. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.

    Moussalli J et al. · Gastroenterol Res Pract · 2010 Match 88

    Barriers to management of HCV in injection drug users are related to…

    ActiTest FibroTest HCV

  33. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 88

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  34. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.

    Xu XY et al. · PLoS One · 2014 Match 87

    Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…

    FibroTest HBV

  35. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 87

    …It reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing…

    FibroTest HCV

  36. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 86

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  37. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 86

    FibroTest HBV

  38. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 86

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  39. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 85

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  40. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 85

    ActiTest FibroTest HCV

  41. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 84

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  42. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 84

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  43. Late presentation of chronic viral hepatitis for medical care: a consensus definition.

    Mauss S et al. · BMC Med · 2017 Match 84

    ### Introduction We present two consensus definitions of advanced and late stage liver…

    FibroTest HBV HCV

  44. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 83

    FibroTest Alcohol

  45. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 83

    ### Aims To evaluate the application of the recently proposed recommendations by the…

    FibroTest NashTest Metabolic

  46. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.

    Bonnard P et al. · Am J Trop Med Hyg · 2010 Match 82

    Liver fibrosis (LF) must be assessed before talking treatment decisions in hepatitis…

    FibroTest HBV

  47. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 82

    ActiTest FibroTest HBV

  48. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 82

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  49. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 81

    ### Background & Aims Although methotrexate (MTX) is used in the effective treatment of…

    FibroTest Other

  50. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 81

    Haemophilia is an entity, wherein the HCV infection rate is greater than…

    FibroTest HCV

  51. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 80

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  52. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Match 80

    In chronic hepatitis C, biopsy is the gold standard for assessment of…

    FibroTest HCV

  53. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.

    Bonnard P et al. · J Viral Hepat · 2015 Match 80

    In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…

    FibroTest HCV

  54. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 79

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  55. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 79

    ### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…

    HCV

  56. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Match 78

    ### Unlabelled The staging of liver fibrosis is pivotal for defining the prognosis…

    FibroTest HCV

  57. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?

    Maor Y et al. · Haemophilia · 2006 Match 78

    Liver biopsy remains the gold standard for the evaluation of fibrosis despite…

    FibroTest HCV

  58. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 78

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  59. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.

    Halfon P et al. · J Hepatol · 2007 Match 77

    ### Background/Aims We evaluated the test performance profile (TPP) of blood tests…

    FibroTest HCV

  60. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007 Match 77

    ### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…

    FibroTest HCV

  61. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Match 76

    ### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…

    FibroTest HCV

  62. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

    de Lédinghen V et al. · J Pediatr Gastroenterol Nutr · 2007 Match 76

    ### Objective Transient elastography (FibroScan) is a novel, noninvasive, rapid bedside method to…

    FibroTest HBV HCV Other

  63. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Match 75

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  64. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 75

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  65. Changes of non-invasive markers and FibroScan values during HCV treatment.

    Vergniol J et al. · J Viral Hepat · 2009 Match 75

    The recent advent of non-invasive methods for assessment of fibrosis allows…

    FibroTest HCV

  66. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.

    Hermeziu B et al. · Gastroenterol Clin Biol · 2010 Match 74

    FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…

    ActiTest FibroTest HCV

  67. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 74

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  68. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 73

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  69. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.

    Castéra L et al. · J Hepatol · 2010 Match 73

    ### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…

    FibroTest HCV

  70. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 73

    ### Background & Aims The aim of this study was to determine the diagnostic…

    FibroTest Alcohol

  71. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014 Match 72

    ### Background The development of esophageal varices is a late complication of chronic…

    FibroTest Other

  72. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 72

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  73. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 71

    ### Purpose Transient elastography (FibroScan, [TE]) and serum fibrosis markers such as the…

    FibroTest Alcohol HBV HCV +2

  74. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 71

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  75. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.

    Bourliere M et al. · Aliment Pharmacol Ther · 2008 Match 71

    ### Background Non-invasive liver fibrosis scores such as Hepascore (HS) have been…

    FibroTest HCV

  76. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.

    Calin R et al. · J Clin Virol · 2013 Match 70

    ### Background Due to common routes of transmission, HIV and HBV are frequently…

    FibroTest HBV HIV

  77. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

    Patel K et al. · J Viral Hepat · 2009 Match 70

    Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…

    FibroTest HCV

  78. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.

    Bosselut N et al. · Clin Chim Acta · 2013 Match 69

    ### Background Noninvasive methods for liver fibrosis evaluation in chronic liver diseases have…

    FibroTest HCV

  79. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 69

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  80. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

    Fontanges T et al. · Gastroenterol Clin Biol · 2008 Match 69

    ### Introduction The purpose of this clinical trial was to determine in routine…

    ActiTest FibroTest HCV

  81. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

    Akuta N et al. · J Gastroenterol · 2018 Match 68

    ### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…

    FibroTest HCV

  82. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

    Zarski JP et al. · J Hepatol · 2012 Match 68

    ### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…

    FibroTest HCV

  83. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 67

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  84. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Match 67

    ### Background/Aims The aim of this study was to compare the performance…

    FibroTest HBV HIV

  85. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.

    Castéra L et al. · J Hepatol · 2009 Match 67

    ### Background/Aims To assess prospectively the accuracy of transient elastography (TE, FibroScan…

    FibroTest HCV

  86. A novel panel of blood markers to assess the degree of liver fibrosis.

    Calès P et al. · Hepatology · 2005 Match 66

    The objective was to develop new blood tests to characterize different fibrosis…

    FibroTest Alcohol HBV HCV

  87. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 66

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  88. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 65

    ### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…

    FibroTest SteatoTest HBV HCV +1

  89. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 65

    ### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…

    FibroTest Other

  90. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 65

    ### Purpose To compare the diagnostic performance of acoustic radiation force impulse (ARFI…

    FibroTest Alcohol HBV HCV +2

  91. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 64

    The aim of this study was to evaluate the diagnostic usefulness of…

    FibroTest Other

  92. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 64

    ### Background/Aims The aim was to identify a panel of biomarkers (AshTest…

    AshTest Alcohol

  93. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 63

    ActiTest FibroTest NashTest-2 Metabolic

  94. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 63

    ActiTest FibroTest HBV

  95. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 63

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  96. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 62

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  97. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 62

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  98. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 61

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  99. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 61

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  100. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.

    Imbert-Bismut F et al. · Clin Chem Lab Med · 2004 Match 61

    Combinations of tests comprising alpha2-macroglobulin, haptoglobin, apolipoprotein Al, gamma-glutamyltransferase, total…

    ActiTest FibroTest HCV

  101. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 60

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  102. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 60

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  103. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 59

    ### Background Urea cycle disorders (UCDs) are among the most common inborn errors…

    ActiTest FibroTest Other

  104. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 59

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  105. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 59

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  106. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 58

    ### Background Noninvasive tests are crucial for the management and follow-up of…

    ActiTest FibroTest AIH

  107. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 58

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver…

    FibroTest HBV HIV

  108. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 57

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  109. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.

    Poynard T et al. · Antivir Ther · 2010 Match 57

    ### Background Liver biopsy and virological end points are standard references for assessing…

    ActiTest FibroTest HBV HCV +1

  110. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 57

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  111. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 56

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  112. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 56

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  113. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 55

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  114. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 55

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  115. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 55

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  116. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 54

    Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…

    ActiTest FibroTest HCV

  117. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 54

    ### Background Chronic HCV is one of the major causes of morbidity and…

    FibroTest HCV

  118. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 53

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  119. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 53

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  120. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 53

    FibroTest SteatoTest Metabolic

  121. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 52

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  122. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 52

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  123. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 51

    FibroTest Alcohol HBV HCV +3

  124. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.